Evidence map›Paper›PMID 39400687›Full record

Observational studyJournal of cancer survivorship : research and practice2026

Association between smoking and prostate cancer survivors' long-term quality of life and function: an analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study.

David-Dan Nguyen, Daniel A Barocas, Zhiguo Zhao, Li-Ching Huang, Tatsuki Koyama, Bashir Al Hussein Ai Awamlh, David F Penson, Alicia K Morgans, Michael Goodman, Ann S Hamilton and 7 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Author response to 01530, Proactive strategies for fracture risk in androgen deprivation therapy: a call for multidisciplinary collaboration.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

David-Dan NguyenDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Li-Ching HuangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Tatsuki KoyamaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Bashir Al Hussein Ai AwamlhDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
David F PensonDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Alicia K MorgansDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michael GoodmanDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
Ann S HamiltonDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Xia-Cheng WuEpidemiology and Population Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Jie LiRutgers Cancer Institute of New Jersey, New Brunswick, NJ and New Jersey State Cancer Registry, Cancer Epidemiology Services, New Jersey Department of Health, New Brunswick, NJ, USA.
Lisa E PaddockRutgers Cancer Institute of New Jersey, New Brunswick, NJ and New Jersey State Cancer Registry, Cancer Epidemiology Services, New Jersey Department of Health, New Brunswick, NJ, USA.
Antoinette M StroupRutgers Cancer Institute of New Jersey, New Brunswick, NJ and New Jersey State Cancer Registry, Cancer Epidemiology Services, New Jersey Department of Health, New Brunswick, NJ, USA.
Brock B O'NeilDepartment of Urology, University of Utah Health, Salt Lake City, UT, USA.
Karen E HoffmanDepartment of Radiation Oncology, The University of Texas MD Anderson Center, Houston, TX, USA.
Christopher J D WallisDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. wallis.cjd@gmail.com.

Funding

Repurposing of a Long-Acting Parathyroid Hormone Analog for the Treatment of HypoparathyroidismZIATR000011 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI YANG, NA · 2015 to 2019
$8.2M
10-year Comparative Effectiveness and Harms of Treatments for Prostate CancerR01CA230352 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BAROCAS, DANIEL A · 2019 to 2023
$3.1M
AHRQ HHS 1R01HS019356, 1R01HS022640National Institutes of Health/National Cancer Institute R01CA230352Patient-Centered Outcomes Research Institute CE-12-11-4667Vanderbilt Institute for Clinical and Translational Research UL1TR000011 from NCATS/NIH
6 · The paper itself

Abstract

purposeThere is limited evidence of tobacco smoking's effect on cancer survivors' quality of life (QOL) and function. As the natural history of localized prostate cancer (PCa) is protracted, there is a need to identify modifiable risk factors that can influence PCa survivorship, such as tobacco smoking. MATERIAL AND

methodsWe used up to 10-year survey data from the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study, a prospective, population-based, observational study of patients diagnosed with localized PCa in 2011-2012. Survivors were categorized as never, former, and current smokers during survivorship. Adjusted multivariable linear regression models were used to assess the association between smoking and 5-year and 10-year scores on the 26-Item Expanded Prostate Index Composite (EPIC-26; PCa-specific domains) and 5-year scores on the Medical Outcomes Study 36-Item Short Form Survey (SF-36; general health domains).

resultsWe included 2426 patients of whom 142 (6%) were current smokers, 1039 (43%) were former smokers, and 1245 (51%) were never smokers. Current smokers were more likely to be Black, low-income, and less formally educated (all p < 0.01). After adjustments, there was no association between smoking history with disease-specific functional outcomes (EPIC-26) at 5 years or 10 years (all p > 0.05). However, in adjusted analyses assessing general health domains (SF-36), compared to participants who never smoked, current smokers during survivorship had worse physical function (- 10.96, 95% CI - 16.37 to - 5.55, p < 0.01) at 5 years.

conclusionPCa survivors who continue to smoke experience worse physical functioning though there is no significant independent effect on PCa-specific functional domains. IMPLICATIONS FOR CANCER SURVIVORS: Prostate cancer survivors who continue to smoke experience worse physical functioning though there is no significant independent effect on PCa-specific functional domains. Smoking cessation may improve prostate cancer survivorship.

Indexed as

Cancer SurvivorsProstatic NeoplasmsQuality of LifeSmokingAgedComparative Effectiveness ResearchHumansMaleMiddle AgedProspective StudiesFunctionProstate cancerQuality of lifeSurvivorshipTobacco smoking

Identifiers

PMID39400687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.